Effects of urapidil and doxazosin on heart rate

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-003660-38-AT

Enrollment

Registered

2005-09-26

Start date

2005-10-31

Completion date

Unknown

Last updated

2016-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy males

Interventions

Trade Name: Ebrantil Product Name: Ebrantil Pharmaceutical Form: Capsule* Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: Ascalan Product Nam

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy male volunteers Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Any known disease, chronic intake of medicine whatsoever

Design outcomes

Primary

Measure	Time frame
Main Objective: Compare effects of urapidil, doxazosin and placebo on heart rate;Secondary Objective: Compare effects of urapidil, doxazosin and placebo on blood pressure;Primary end point(s): Heart rate at 4 hours following oral drug intake	—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026